Skip to main content

The Cooper Companies company profile

  • COO · Nasdaq
  • Medical devices
  • Health Care Supplies
  • S&P 500
$62.65+0.74%Close 13 Nov 2026 · Market value $11.91B · Next results 3 Dec 2026

About The Cooper Companies

The Cooper Companies, Inc. is a global medical device company headquartered in San Ramon, California, selling products in over 130 countries. It operates two business segments. CooperVision manufactures contact lenses, including single-use, two-week and monthly lenses in spherical, toric and multifocal designs, and myopia management products such as the MiSight 1 day lens. CooperSurgical offers products and services in fertility and women's health, including medical devices used in gynecology, obstetrics and labor and delivery, fertility laboratory products, cryostorage of cord blood and cord tissue, genomic services, and the Paragard intrauterine device. CooperVision sells to optical chains, global retailers, buying groups and mass merchandisers, while CooperSurgical sells to OB/GYN and medical offices, hospitals, ambulatory surgery centers, fertility clinics and directly to consumers.

A summary of the business section of the company's latest annual report, filed 5 Dec 2025.

Company facts

TickerCOO · Nasdaq
SectorMedical devices
IndustryHealth Care Supplies
IndexS&P 500
Fiscal year ends31 October
Reporting currencyUSD
CIK711404
Latest annual report10-K, filed 5 Dec 2025

Officers and directors

NameRoleShares ownedLatest Form 4
Albert G. White IIIPresident & CEO · Director1.9M · 1%Shares withheld for tax, 8 Jan 2026
Daniel G. McBrideEVP & Chief Operating Officer686K · < 1%Option exercise, 8 Jan 2026
Robert S. WeissDirector547K · < 1%Option exercise, 1 Apr 2026
Holly R. SheffieldPresident, CSI358K · < 1%Option exercise, 8 Jan 2026
Brian G. AndrewsEVP, CFO & Treasurer350K · < 1%Option exercise, 8 Jan 2026
Gerard H. Warner IIIPresident, CooperVision, Inc.91.1K · < 1%Shares withheld for tax, 8 Jan 2026
Colleen E. JayDirector36.6K · < 1%Option exercise, 1 Apr 2026
Teresa S. MaddenDirector12.4K · < 1%Option exercise, 1 Apr 2026
Maria Rivas, M.D.Director11.1K · < 1%Option exercise, 1 Apr 2026
Walter M Rosebrough, Jr.Director10.0K · < 1%Open-market purchase, 14 Sep 2026
Cynthia L. LuccheseDirector9.4K · < 1%Option exercise, 1 Apr 2026
Lawrence E. KurziusDirector7.8K · < 1%Open-market purchase, 16 Sep 2026
Barbara A. CarboneDirector0 · < 1%Option exercise, 1 Apr 2026
Keel Paul ADirector—Open-market purchase, 11 Sep 2026
KOZY WILLIAM ADirector—Option exercise, 1 Apr 2025
Ricupati AgostinoSVP & CAO—Option exercise, 1 Apr 2025
Khadder NicholasVP, General Counsel & Corp Sec—Option exercise, 8 Jan 2025

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

COO in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.